Recent discussions surrounding the 340B Drug Pricing Program have highlighted significant concerns regarding its effectiveness and impact on healthcare costs. An investigation by STAT news coincided with testimonies from executives of major pharmacy benefit managers (PBMs) before the House Oversight Committee, asserting that they pass through nearly all rebates. Critics argue that the 340B program is flawed, as it primarily benefits large hospital conglomerates rather than patients, shifting resources away from payers and pharmaceutical companies. The Federal Trade Commission is also considering an antitrust lawsuit against PBMs, with discussions in the Wall Street Journal emphasizing the need for reform. Additionally, the Department of Health and Human Services Office of Inspector General has underscored the importance of anti-fraud safeguards in refund and discount programs aimed at reducing drug costs. The ongoing debates include the complexities of Medicaid rebates and 340B discounts, particularly in relation to Medicare negotiated prices, with industry experts calling for a linkage of discounts directly to beneficiaries. The implications of these discussions are expected to influence the redesign of Part D plans and the bidding process for 2025.